Cytomegalovirus‐associated chorioretinitis after liver transplantation: case report and review of the literature

Abstract: A cytomegalovirus (CMV) donor positive/recipient negative liver transplant recipient developed CMV syndrome with presumed colitis 2 weeks after discontinuing the standard 3 months of valganciclovir prophylaxis. Treatment with intravenous ganciclovir (GCV) reduced, but did not clear, CMV replication. A CMV UL97 mutation (M460V) conferring GCV resistance was identified. Reduction of immunosuppression was followed by rapidly rising lymphocyte counts as well as by clearance of CMV viremia and of clinical symptoms. However, bilateral chorioretinitis was diagnosed 2 weeks later and treated with foscarnet and cidofovir. Then, right eye vitritis occurred necessitating vitrectomy due to a partially rhegmatogeneous retinal detachment. Because chorioretinitis–vitritis after rising lymphocyte counts and clearance of CMV viremia was strongly suggestive of an immune reconstitution syndrome (IRS)‐like disease, we investigated CMV‐specific T‐cells in the peripheral blood available during follow‐up. We found strong CD8+ but only low CD4+ T‐cell responses (4.77% vs.<0.1%) to the CMV immediate early pp72, while responses to CMV‐lysate or CMV‐pp65 (CD4+ <0.01%; CD8+<0.01%) were low. Over 16 weeks of follow‐up, pp72‐specific CD8+ responses declined, while responses to pp65 gradually increased (CD4+ 0.16%; CD8+ 0.76%) indicating a slowly adapting CMV‐specific cellular T‐cell response. Review of 12,653 published liver transplant patients identified only 14 (0.1%) reported cases of CMV‐associated chorioretinitis at a median 41.7 weeks post transplant. CMV‐associated opthalmologic complications late post transplantation may possibly involve 2 different entities of cytopathic retinitis and IRS‐like chorioretinitis–vitritis.

[1]  Nina Khanna,et al.  Cytomegalovirus and polyomavirus BK posttransplant. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[2]  D. Lilleri,et al.  Inconsistent Responses of Cytomegalovirus‐Specific T Cells to pp65 and IE‐1 versus Infected Dendritic Cells in Organ Transplant Recipients , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[3]  M. Mihatsch,et al.  Transient allograft dysfunction from immune reconstitution in a patient with polyoma BK-virus-associated nephropathy. , 2007, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[4]  A. Limaye,et al.  Longitudinal assessment of cytomegalovirus (CMV)-specific immune responses in liver transplant recipients at high risk for late CMV disease. , 2007, The Journal of infectious diseases.

[5]  D. Correa,et al.  Acute infection of Toxoplasma gondii and cytomegalovirus reactivation in a pediatric patient receiving liver transplant , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[6]  C. Mengelle,et al.  Monitoring human cytomegalovirus (HCMV) in HCMV-seropositive orthotopic liver-transplant recipients by means of quantitative real-time polymerase chain reaction. , 2006, Experimental and clinical transplantation : official journal of the Middle East Society for Organ Transplantation.

[7]  S. Weigand,et al.  Effect of antiviral chemoprophylaxis on adverse clinical outcomes associated with cytomegalovirus after liver transplantation. , 2006, Mayo Clinic proceedings.

[8]  C. Marroni,et al.  Risk factors associated with cytomegalovirus infection in orthotopic liver transplant patients. , 2006, Transplantation proceedings.

[9]  Valeria Ghisetti,et al.  Quantitation of cytomegalovirus DNA by real‐time polymerase chain reaction in peripheral blood specimens of patients with solid organ transplants: Comparison with end‐point PCR and pp65 antigen test , 2006, Journal of medical virology.

[10]  A. Limaye,et al.  Impact of Cytomegalovirus in Organ Transplant Recipients in the Era of Antiviral Prophylaxis , 2006, Transplantation.

[11]  L. Krogerus,et al.  Cytomegalovirus infection of the liver transplant: virological, histological, immunological, and clinical observations , 2006, Transplant infectious disease : an official journal of the Transplantation Society.

[12]  S. Shelburne,et al.  Immune reconstitution inflammatory syndrome: more answers, more questions. , 2006, The Journal of antimicrobial chemotherapy.

[13]  R. Fontana,et al.  Efficacy and safety of low‐dose valganciclovir in the prevention of cytomegalovirus disease in adult liver transplant recipients , 2006, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[14]  G. Klintmalm,et al.  Allograft loss in renal transplant recipients with cryptococcus neoformans associated immune reconstitution syndrome. , 2005, Transplantation.

[15]  Chao-Long Chen,et al.  The renal‐sparing efficacy of basiliximab in adult living donor liver transplantation , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[16]  H. Hirsch BK virus: opportunity makes a pathogen. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[17]  U. Neumann,et al.  Changing impact of cytomegalovirus in liver transplantation – a single centre experience of more than 1000 transplantations without ganciclovir prophylaxis , 2005, Transplant international : official journal of the European Society for Organ Transplantation.

[18]  D. Mann,et al.  Negative Impact of Human Leukocyte Antigen Matching in the Outcome of Polyomavirus Nephropathy , 2005, Transplantation.

[19]  B. Gridelli,et al.  Basiliximab in a triple-drug regimen with tacrolimus and steroids in liver transplantation. , 2005, Transplantation proceedings.

[20]  G. Klintmalm,et al.  An immune reconstitution syndrome-like illness associated with Cryptococcus neoformans infection in organ transplant recipients. , 2005, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[21]  P. Martín-Dávila,et al.  Analysis of a quantitative PCR assay for CMV infection in liver transplant recipients: an intent to find the optimal cut-off value. , 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[22]  Nina Singh,et al.  Who among cytomegalovirus‐seropositive liver transplant recipients is at risk for cytomegalovirus infection? , 2005, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[23]  D. Mutimer,et al.  Impact of targeted oral ganciclovir prophylaxis for transplant recipients of livers from cytomegalovirus‐seropositive donors , 2005, Transplant infectious disease : an official journal of the Transplantation Society.

[24]  M. Pescovitz,et al.  Clinical Utility of Cytomegalovirus (CMV) Serology Testing in High‐risk CMV D+/R− Transplant Recipients , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[25]  R. Hetzer,et al.  Protection from cytomegalovirus after transplantation is correlated with immediate early 1–specific CD8 T cells , 2005, The Journal of experimental medicine.

[26]  Nina Singh,et al.  Efficacy of Valganciclovir Administered as Preemptive Therapy for Cytomegalovirus Disease in Liver Transplant Recipients: Impact on Viral Load and Late-Onset Cytomegalovirus Disease , 2005, Transplantation.

[27]  B. Alexander,et al.  Risk Factors for Cytomegalovirus Viremia and Disease Developing after Prophylaxis in High-Risk Solid-Organ Transplant Recipients , 2004, Transplantation.

[28]  A. Limaye,et al.  Late-Onset Cytomegalovirus Disease in Liver Transplant Recipients Despite Antiviral Prophylaxis1 , 2004, Transplantation.

[29]  P. Price,et al.  Immune restoration disease after antiretroviral therapy , 2004, AIDS.

[30]  M. McCulloch,et al.  LIVER TRANSPLANTATION FOR CHILDREN – RED CROSS CHILDREN’S HOSPITAL EXPERIENCE , 2004 .

[31]  M. Wagener,et al.  T‐helper cell responses in liver transplant recipients: correlation with cytomegalovirus and other major infections , 2004, Transplant infectious disease : an official journal of the Transplantation Society.

[32]  S. Fan,et al.  Interleukin‐2 receptor antibody (basiliximab) for immunosuppressive induction therapy after liver transplantation: A protocol with early elimination of steroids and reduction of tacrolimus dosage , 2004, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[33]  M. Battegay,et al.  Immune reconstitution in HIV-infected patients. , 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[34]  M. V. Van Natta,et al.  Results of a cytomegalovirus (CMV)-specific CD8+/interferon- gamma+ cytokine flow cytometry assay correlate with clinical evidence of protective immunity in patients with AIDS with CMV retinitis. , 2004, The Journal of infectious diseases.

[35]  M. McCulloch,et al.  Liver transplantation for children – the Red Cross Children's Hospital experience , 2004, Pediatric transplantation.

[36]  R. Busuttil,et al.  Randomized controlled trial of sequential intravenous and oral ganciclovir versus prolonged intravenous ganciclovir for long-term prophylaxis of cytomegalovirus disease in high-risk cytomegalovirus-seronegative liver transplant recipients with cytomegalovirus-seropositive donors , 2004, Transplantation.

[37]  P. Nyckowski,et al.  Cytomegalovirus infection as a common complication following liver transplantation. , 2003, Transplantation proceedings.

[38]  S. Singhal,et al.  Cytomegalovirus disease following liver transplantation: an analysis of prophylaxis strategies. , 2003, The Journal of infection.

[39]  Thomas F. Smith,et al.  Dynamics of cytomegalovirus replication during preemptive therapy with oral ganciclovir. , 2003, The Journal of infectious diseases.

[40]  D. Wolf,et al.  Late cytomegalovirus disease following liver transplantation , 2002, Transplant international : official journal of the European Society for Organ Transplantation.

[41]  M. L. de la Mata,et al.  Pre-emptive oral ganciclovir can reduce the risk of cytomegalovirus disease in liver transplant recipients. , 2002, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[42]  J. S. Daly,et al.  Preemptive Strategy for Ganciclovir Administration Against Cytomegalovirus in Liver Transplantation Recipients , 2002, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[43]  S. Riddell,et al.  Association between immune recovery uveitis and a diverse intraocular cytomegalovirus-specific cytotoxic T cell response. , 2002, The Journal of infectious diseases.

[44]  M. Lappalainen,et al.  Monitoring of Viral Load by Quantitative Plasma PCR during Active Cytomegalovirus Infection of Individual Liver Transplant Patients , 2002, Journal of Clinical Microbiology.

[45]  N. Heaton,et al.  Cytomegalovirus infection after liver transplantation: viral load as a guide to treating clinical infection , 2002, Transplantation.

[46]  P. Price,et al.  Cytomegalovirus (CMV) retinitis immune restoration disease occurs during highly active antiretroviral therapy-induced restoration of CMV-specific immune responses within a predominant Th2 cytokine environment. , 2002, The Journal of infectious diseases.

[47]  Thomas F. Smith,et al.  Preemptive use of oral ganciclovir to prevent cytomegalovirus infection in liver transplant patients: a randomized, placebo-controlled trial. , 2002, The Journal of infectious diseases.

[48]  K. Batts,et al.  Impact of cytomegalovirus infection, year of transplantation, and donor age on outcomes after liver transplantation for hepatitis C , 2002, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[49]  T. Larson,et al.  Allograft rejection predicts the occurrence of late-onset cytomegalovirus (CMV) disease among CMV-mismatched solid organ transplant patients receiving prophylaxis with oral ganciclovir. , 2001, The Journal of infectious diseases.

[50]  M. Chen,et al.  Association between cytomegalovirus-specific reactivity of T cell subsets and development of cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome. , 2001, The Journal of infectious diseases.

[51]  P. Price,et al.  Immune dysfunction and immune restoration disease in HIV patients given highly active antiretroviral therapy. , 2001, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

[52]  U. Settmacher,et al.  PROSPECTIVE RANDOMIZED TRIAL TO ASSESS THE VALUE OF PREEMPTIVE ORAL THERAPY FOR CMV INFECTION FOLLOWING LIVER TRANSPLANTATION , 2001, Transplantation.

[53]  A. Meyerhans,et al.  LEVELS OF VIRUS-SPECIFIC CD4 T CELLS CORRELATE WITH CYTOMEGALOVIRUS CONTROL AND PREDICT VIRUS-INDUCED DISEASE AFTER RENAL TRANSPLANTATION1 , 2001, Transplantation.

[54]  J. Lerut,et al.  USE OF MYCOPHENOLATE MOFETIL AS RESCUE THERAPY AFTER PEDIATRIC LIVER TRANSPLANTATION , 2001, Transplantation.

[55]  C. Sabin,et al.  Relationship between IgM antibody to human cytomegalovirus, virus load, donor and recipient serostatus, and administration of methylprednisolone as risk factors for cytomegalovirus disease after liver transplantation. , 2000, The Journal of infectious diseases.

[56]  M. Sterneck,et al.  A prospective study comparing safety and efficacy of mycophenolate mofetil versus azathioprine in primary liver transplant recipients. , 2000, Transplantation proceedings.

[57]  Nina Singh,et al.  CYTOMEGALOVIRUS ANTIGENEMIA DIRECTED PRE-EMPTIVE PROPHYLAXIS WITH ORAL VERSUS I.V. GANCICLOVIR FOR THE PREVENTION OF CYTOMEGALOVIRUS DISEASE IN LIVER TRANSPLANT RECIPIENTS1: A Randomized, Controlled Trial , 2000, Transplantation.

[58]  D. Schoenfeld,et al.  Prevention of primary cytomegalovirus disease in organ transplant recipients with oral ganciclovir or oral acyclovir prophylaxis , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[59]  P. Francioli,et al.  Preemptive treatment approach to cytomegalovirus (CMV) infection in solid organ transplant patients: relationship between compliance with the guidelines and prevention of CMV morbidity , 2000, Transplant infectious disease : an official journal of the Transplantation Society.

[60]  W. Bechstein,et al.  Infectious complications after orthotopic liver transplantation with different immunosuppressive induction regimens. , 2000, Transplantation proceedings.

[61]  R. Rubin,et al.  Prevention dof recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir , 2000 .

[62]  V. Balakrishnan,et al.  Quantitation of peripheral blood cytomegalovirus DNA for monitoring recurrent cytomegalovirus retinitis in pediatric solid organ transplant recipients , 2000, Pediatric transplantation.

[63]  J. Andersson,et al.  High‐dose acyclovir prophylaxis reduces cytomegalovirus disease in liver transplant patients , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[64]  R. Rubin,et al.  Prevention of recurrent cytomegalovirus disease in renal and liver transplant recipients: effect of oral ganciclovir. , 1999, Transplant infectious disease : an official journal of the Transplantation Society.

[65]  W. Freeman,et al.  Incidence of immune recovery vitritis in cytomegalovirus retinitis patients following institution of successful highly active antiretroviral therapy. , 1999, The Journal of infectious diseases.

[66]  R. Rubin,et al.  Effect of oral acyclovir or ganciclovir therapy after preemptive intravenous ganciclovir therapy to prevent cytomegalovirus disease in cytomegalovirus seropositive renal and liver transplant recipients receiving antilymphocyte antibody therapy. , 1998, Transplantation.

[67]  R. Wiesner,et al.  Significance of cytomegalovirus for long-term survival after orthotopic liver transplantation: a prospective derivation and validation cohort analysis. , 1998, Transplantation.

[68]  D. Paterson,et al.  Infectious complications occurring in liver transplant recipients receiving mycophenolate mofetil. , 1998, Transplantation.

[69]  U. Neumann,et al.  A randomized, placebo-controlled trial with anti-interleukin-2 receptor antibody for immunosuppressive induction therapy after liver transplantation. , 1998, Clinical transplantation.

[70]  R. Wiesner,et al.  Clinical significance of viral load in the diagnosis of cytomegalovirus disease after liver transplantation. , 1998, Transplantation.

[71]  J. Gavaldà,et al.  Cytomegalovirus disease as a risk factor for graft loss and death after orthotopic liver transplantation. , 1998, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[72]  P. McCluskey,et al.  Ocular complications of heart, lung, and liver transplantation , 1998, The British journal of ophthalmology.

[73]  W. Freeman,et al.  Immune recovery vitritis associated with inactive cytomegalovirus retinitis: a new syndrome. , 1998, Archives of ophthalmology.

[74]  J. Contreras,et al.  Tacrolimus (FK506) and mycophenolate mofetil combination therapy versus tacrolimus in adult liver transplantation. , 1998, Transplantation.

[75]  R. Busuttil,et al.  Long-term ganciclovir prophylaxis for successful prevention of primary cytomegalovirus (CMV) disease in CMV-seronegative liver transplant recipients with CMV-seropositive donors. , 1997, Transplantation.

[76]  M. Pescovitz,et al.  Randomised trial of efficacy and safety of oral ganciclovir in the prevention of cytomegalovirus disease in liver-transplant recipients , 1997, The Lancet.

[77]  J. Reyes,et al.  Comparison of intravenous ganciclovir followed by oral acyclovir with intravenous ganciclovir alone for prevention of cytomegalovirus and Epstein-Barr virus disease after liver transplantation in children. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[78]  R. Busuttil,et al.  Randomized comparison of ganciclovir plus intravenous immune globulin (IVIG) with IVIG alone for prevention of primary cytomegalovirus disease in children receiving liver transplants. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[79]  J. Gavaldà,et al.  Two grams daily of oral acyclovir reduces the incidence of cytomegalovirus disease in CMV‐seropositive liver transplant recipients , 1997, Transplant international : official journal of the European Society for Organ Transplantation.

[80]  J. Griffith,et al.  Cytomegalovirus immune globulin (CMVIG) prophylaxis is associated with increased survival after orthotopic liver transplantation. The Boston Center for Liver Transplantation CMVIG Study Group. , 1997, Clinical transplantation.

[81]  R. Dalton,et al.  Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy , 1997, The Lancet.

[82]  M. Emond,et al.  Induction immunosuppressive therapy is associated with a low rejection rate after liver transplantation. , 1997, Clinical transplantation.

[83]  R. Wiesner,et al.  Prophylaxis of cytomegalovirus infection in liver transplantation: a randomized trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. , 1997, Transplantation.

[84]  G. Papanicolaou,et al.  Infectious ocular complications in orthotopic liver transplant patients. , 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[85]  E. Elias,et al.  Patterns of viremia in liver transplant recipients with symptomatic cytomegalovirus infection. , 1997, Transplantation.

[86]  D. Snydman,et al.  Primary cytomegalovirus infection in liver transplant recipients: comparison of infections transmitted via donor organs and via transfusions. Boston Center for Liver Transplantation CMVIG Study Group. , 1996, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[87]  W. Bechstein,et al.  The importance of late infections for the long‐term outcome after liver transplantation , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[88]  D. Snydman,et al.  Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients , 1996 .

[89]  K. St. George,et al.  Time to detection of cytomegalovirus (CMV) DNA in blood leukocytes is a predictor for the development of CMV disease in CMV-seronegative recipients of allografts from CMV-seropositive donors following liver transplantation. , 1996, The Journal of infectious diseases.

[90]  R. Vaughan,et al.  Antibody removal and subsequent transplantation of a highly sensitised paediatric renal patient , 1996, Transplant international : official journal of the European Society for Organ Transplantation.

[91]  R. Wiesner,et al.  Prognostic significance and risk factors of untreated cytomegalovirus viremia in liver transplant recipients. , 1996, The Journal of infectious diseases.

[92]  R. Busuttil,et al.  Long-term ganciclovir prophylaxis eliminates serious cytomegalovirus disease in liver transplant recipients receiving OKT3 therapy for rejection. , 1995, Transplantation.

[93]  J. Neuberger,et al.  Quantitation of cytomegalovirus in the blood of liver transplant recipients. , 1995, Liver transplantation and surgery : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[94]  R. Busuttil,et al.  Randomised comparison of ganciclovir and high-dose acyclovir for long-term cytomegalovirus prophylaxis in liver-transplant recipients , 1995, The Lancet.

[95]  R. Wiesner,et al.  OKT3 treatment for allograft rejection is a risk factor for cytomegalovirus disease in liver transplantation. , 1995, The Journal of infectious diseases.

[96]  B. Meyers,et al.  High-dose acyclovir and intravenous immune globulin reduce the incidence of CMV disease after liver transplantation , 1995, Transplant international : official journal of the European Society for Organ Transplantation.

[97]  A. Niveleau,et al.  Monitoring levels of human cytomegalovirus DNA in blood after liver transplantation , 1995, Journal of clinical microbiology.

[98]  W. Bechstein,et al.  Comparison of FK506- and cyclosporine-based immunosuppression in primary orthotopic liver transplantation. A single center experience. , 1995, Transplantation.

[99]  T. Peters,et al.  Cold Ischemia And Outcome In 17,937 Cadaveric Kidney Transplants , 1995, Transplantation.

[100]  K. St. George,et al.  Diagnosis of cytomegalovirus infections by shell vial assay and conventional cell culture during antiviral prophylaxis , 1994, Journal of clinical microbiology.

[101]  T. Starzl,et al.  A PROSPECTIVE RANDOMIZED TRIAL COMPARING SEQUENTIAL GANCICLOVIR‐HIGH DOSE ACYCLOVIR TO HIGH DOSE ACYCLOVIR FOR PREVENTION OF CYTOMEGALOVIRUS DISEASE IN ADULT LIVER TRANSPLANT RECIPIENTS , 1994, Transplantation.

[102]  M. Samore,et al.  Risk factors for invasive fungal infections complicating orthotopic liver transplantation. , 1994, The Journal of infectious diseases.

[103]  R. Wiesner,et al.  Detection of cytomegalovirus DNA in sera of liver transplant recipients , 1994, Journal of clinical microbiology.

[104]  Nina Singh,et al.  High-Dose Acyclovir Compared with Short-Course Preemptive Ganciclovir Therapy To Prevent Cytomegalovirus Disease in Liver Transplant Recipients , 1994, Annals of Internal Medicine.

[105]  S. Hammer,et al.  Cytomegalovirus Immune Globulin Prophylaxis in Liver Transplantation , 1993, Annals of Internal Medicine.

[106]  G. Cleghorn,et al.  Cytomegalovirus infection after liver transplantation in children , 1993, Journal of gastroenterology and hepatology.

[107]  J. Preiksaitis,et al.  Cytomegalovirus disease in liver transplant recipients: impact of acyclovir prophylaxis. , 1993, Transplantation proceedings.

[108]  R. Chaisson,et al.  Incidence and natural history of cytomegalovirus disease in patients with advanced human immunodeficiency virus disease treated with zidovudine. The Zidovudine Epidemiology Study Group. , 1992, The Journal of infectious diseases.

[109]  C. Payá,et al.  Low predictive value of polymerase chain reaction for diagnosis of cytomegalovirus disease in liver transplant recipients , 1992, Journal of clinical microbiology.

[110]  F. Luks,et al.  Infectious complications of pediatric liver transplantation. , 1991, Journal of pediatric surgery.

[111]  E. Roberts,et al.  Cytomegalovirus infections in pediatric liver transplantation. , 1990, American journal of diseases of children.

[112]  Meyers Jd,et al.  Prophylaxis of cytomegalovirus infection. , 1990, Seminars in hematology.

[113]  R. Calne,et al.  Viral and toxoplasma gondii infections in children after liver transplantation. , 1990, Journal of clinical pathology.

[114]  R. Stratta,et al.  Clinical patterns of cytomegalovirus disease after liver transplantation. , 1989, Archives of surgery.

[115]  R. Wiesner,et al.  Cytomegalovirus hepatitis in liver transplantation: prospective analysis of 93 consecutive orthotopic liver transplantations. , 1989, The Journal of infectious diseases.

[116]  J. Ludwig,et al.  Rapid shell vial culture and tissue histology compared with serology for the rapid diagnosis of cytomegalovirus infection in liver transplantation. , 1989, Mayo Clinic proceedings.

[117]  W. V. van Son,et al.  Comparison between viremia and antigenemia for detection of cytomegalovirus in blood , 1988, Journal of clinical microbiology.

[118]  S. Hammer,et al.  GANCICLOVIR THERAPY OF SEVERE CYTOMEGALOVIRUS INFECTIONS IN SOLID‐ORGAN TRANSPLANT RECIPIENTS , 1988, Transplantation.

[119]  T. Starzl,et al.  Infections with cytomegalovirus and other herpesviruses in 121 liver transplant recipients: transmission by donated organ and the effect of OKT3 antibodies. , 1988, The Journal of infectious diseases.

[120]  H. Balfour,et al.  Cytomegalovirus infection of the liver in transplant recipients. , 1987, Journal of clinical gastroenterology.

[121]  H. Balfour,et al.  Ganciclovir treatment of cytomegalovirus disease in transplant recipients and other immunocompromised hosts. , 1987, JAMA.

[122]  T. Starzl,et al.  Decreased incidence of viral infections in liver transplant recipients , 2005, Digestive Diseases and Sciences.

[123]  M. Makuuchi,et al.  Risk factors of cytomegalovirus infection after living donor liver transplantation. , 2005, Hepato-gastroenterology.

[124]  D. Snydman,et al.  Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study. , 2001, Transplantation proceedings.

[125]  T. Drewniak,et al.  Diagnosis and monitoring of cytomegalovirus infection after liver transplantation in children. , 1996, Annals of transplantation.

[126]  D. Snydman,et al.  Incidence and predictors of cytomegalovirus pneumonia in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG Study Group. , 1996, Transplantation.

[127]  M. Chobanian,et al.  Changing spectrum of pediatric renal transplantation. , 1994, Transplantation proceedings.

[128]  T. F. Smith,et al.  Risk factors for cytomegalovirus and severe bacterial infections following liver transplantation: a prospective multivariate time-dependent analysis. , 1993, Journal of hepatology.